EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

2′-Fucosyllactose Effects on Preterm Growth, Tolerance, and Neurobehavior: A Double-Blind, Randomized, Placebo-Controlled Pilot

Ethan A Mezoff iD, Qing Duan, Nicholas J Ollberding iD, Elizabeth J Reverri iD, Rachael H Buck iD, Bridget Barrett-Reis, Kimberly Yolton iD, Ardythe L Morrow

Nutrients · 26.07.2026 · 18 (15) · 2437

DOI: 10.3390/nu18152437 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 26.07.2026. Verfasst von Ethan A Mezoff und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, The Ohio State University College of Medicine, Col…. Hauptthemen laut MEDLINE: Trisaccharides, Infant, Premature, Infant Behavior, Dietary Supplements. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Nutrition.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Preterm infants confront multiple coexistent health risks and may not receive human milk (HM), which contains human milk oligosaccharides (HMOs), among other biologically active, beneficial components. 2′-Fucosyllactose (2′-FL) is the most abundant HMO in most HM. Interventional studies of formula with added HMOs have demonstrated multiple beneficial outcomes in healthy, term infants.

Methods

This double-blind, randomized, placebo-controlled pilot study (NCT03306316) evaluated the effect of a 2′-FL supplement on growth, tolerance, and neurobehavior, as assessed by the Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale (NNNS), in preterm infants. Eligible neonates born between 26 0/7 and 31 6/7 weeks gestational age (GA) were enrolled from three NICUs in the United States. Preterm infants consuming mother’s own milk or donor human milk were randomized to receive a supplement of 0.135 g/mL of 2′-FL or 0.05 g/mL dextrose (placebo) twice daily until 36 weeks corrected GA, NNNS assessment, or hospital discharge, whichever came first.

Results

Of 42 participating preterm infants, 23 (55%) received 2′-FL and demonstrated no significant differences in growth in weight, length, or head circumference over 5 weeks. There were also no differences in stool frequency, adverse (AEs) or serious adverse events (SAEs), or neurobehavior (NNNS) between groups.

Conclusions

This pilot study found that 2′-FL supplementation in preterm infants through 36 weeks corrected GA was safe and well-tolerated and supported adequate growth and neurobehavior.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrisaccharidesInfant, PrematureInfant BehaviorDietary SupplementsHumansPilot ProjectsDouble-Blind MethodInfant, NewbornFemaleMilk, HumanMaleGestational Age

Stichwörter der Autor:innen

2′-Fucosyllactosegrowthhuman milk oligosaccharidesneurobehaviorpretermtolerance

Substanzen

Trisaccharides2'-fucosyllactose

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH 43205, USA.
  • Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
  • Nutrition Science & Innovation, Abbott Nutrition, Columbus, OH 43219, USA.
  • Gut, Immunity, and Brain Health Platform, Abbott Nutrition, Columbus, OH 43219, USA.
  • Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

ORCID-Profile: Ethan A Mezoff, Nicholas J Ollberding, Elizabeth J Reverri, Rachael H Buck, Kimberly Yolton

Förderung

  • Abbott Nutrition

Zitieren

APA

Mezoff, E. A., Duan, Q., Ollberding, N. J., Reverri, E. J., Buck, R. H., Barrett-Reis, B., Yolton, K., & Morrow, A. L. (2026). 2′-Fucosyllactose Effects on Preterm Growth, Tolerance, and Neurobehavior: A Double-Blind, Randomized, Placebo-Controlled Pilot. Nutrients, 18(15), 2437. https://doi.org/10.3390/nu18152437

Vancouver

Mezoff EA, Duan Q, Ollberding NJ, Reverri EJ, Buck RH, Barrett-Reis B, et al. 2′-Fucosyllactose Effects on Preterm Growth, Tolerance, and Neurobehavior: A Double-Blind, Randomized, Placebo-Controlled Pilot. Nutrients. 2026;18(15):2437. doi:10.3390/nu18152437

BibTeX
@article{Mezoff2026,
  author = {Mezoff, Ethan A and Duan, Qing and Ollberding, Nicholas J and Reverri, Elizabeth J and Buck, Rachael H and Barrett-Reis, Bridget and Yolton, Kimberly and Morrow, Ardythe L},
  title = {2′-Fucosyllactose Effects on Preterm Growth, Tolerance, and Neurobehavior: A Double-Blind, Randomized, Placebo-Controlled Pilot},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2437},
  doi = {10.3390/nu18152437}
}
Kostenlos starten →